Others have shown that overexpression of CDC20 indicates unfavorable prognosis and poor response to endocrine therapy in ER + breast cancer (Alfarsi et al., 2019; Tang et al., 2019); in contrast, we discovered that CDC20 was related to worse prognosis only in the TNBC subtype, and we think that the different datasets that we analyzed result in the inconsistency. Here, CDC20 is linked to breast cancer.